Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Acquisitions & Divestments (2020 - 2025)

BridgeBio Pharma's Change in Acquisitions & Divestments history spans 6 years, with the latest figure at $11.0 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments changed N/A year-over-year to $11.0 million; the TTM value through Dec 2025 reached $11.0 million, down 88.42%, while the annual FY2025 figure was $11.0 million, 88.42% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $11.0 million at BridgeBio Pharma, down from $40.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $186.7 million in Q1 2022 and bottomed at -$234.2 million in Q3 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $26.0 million (2022), against an average of $19.0 million.
  • The largest annual shift saw Change in Acquisitions & Divestments plummeted 514.5% in 2021 before it skyrocketed 251.27% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $29.4 million in 2021, then fell by 18.37% to $24.0 million in 2022, then grew by 16.67% to $28.0 million in 2023, then skyrocketed by 42.83% to $40.0 million in 2024, then tumbled by 72.5% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Change in Acquisitions & Divestments are $11.0 million (Q4 2025), $40.0 million (Q3 2024), and -$8.2 million (Q2 2024).